Needham Maintains Buy on Harmony Biosciences Hldgs, Raises Price Target to $50

Benzinga Newsdesk www.benzinga.com Positive 83.5%

Neg 0% Neu 0% Pos 83.5%

Needham analyst Ami Fadia maintains Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Buy and raises the price target from $45 to $50.